Progress and Implication of FDA Risk Communication in the United States

Abstract

Abstract: Objective To provide suggestions for drug risk communication in China by introducing the development and implementation effect of FDA risk communication system. Methods The material of FDA risk communication was summarized through the method of literature analysis and searching FDA official website. Results The development of FDA risk communication is more perfect, and through continuous exploration and practice FDA has formed a sound risk communication system and built up a perfect communication platform. Conclusion The drug risk communication is still weak in China. It is urgent to pay attention to Chinese risk communication and establish the sharing platform of risk communication. China should draw experiences from FDA to promote the development and improvement of Chinese drug risk communication from four aspects of focus, model, way and strategy.

Key words: risk communication, progress, way

CLC Number:

TIAN Yi, YANG Yue, TIAN Li-juan. Progress and Implication of FDA Risk Communication in the United States [J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 24-27.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2016/V13/I1/24

References

[1] 李姗, 杨悦. 美国和加拿大药品风险沟通方法及其对我国的启示[J]. 中国新药杂志,2012,21(18):2104-2108.
[2] Motl S, Timpe E, Eichner S. Proposal to improve Med-Watch:decentralized, regional surveillance of adverse drug reactions[J]. Am J Health Syst Pharm, 2004, 61(17):1840.
[3] 孔雅惠. 全球药物不良反应监测系统概述[J]. 药物流行病学杂志,2011,20 (7):364-367.
[4] FDA. Managing the Risks from Medical Product Use: Report to the FDA Commissioner from the Task Force on Risk Management[EB/OL]. (1999-05)[2015-06-16]. http://www.fda.gov / Safety / Safety of Specific Products /ucm180325.htm.
[5] 魏晶, 潘卫三, 杨悦. FDA 与公众的药品安全信息交流指南对我国的启示[J]. 中国新药杂志,2009, 18(14):1287-1290.
[6] FDA. The Future of Drug Safety—Promoting and Protecting the of the Public[EB/OL].(2007-01)[2015-06-16]. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm171627.pdf.
[7] FDA. Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry[EB/OL].(2015-04)[2015-06-18].
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm441226.pdf.
[8] FDA.Guidance Drug Safety Information-FDA’s Communication to the Public[EB/OL](2007-03) [2015-06-18]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072281.pdf.
[9] FDA. FDA’s Strategic Plan for Risk Communication[EB/OL].(2015-07-02) [2015-06-18]. http://www.fda.gov/aboutfda/reportsmanualsforms/reports/ucm183673.htm.
[10] FDA. Milestones in U.S. Food and Drug Law History[EB/OL].(2015-09-21) [2015-10-11]. http://www.fda.gov/AboutFDA/WhatWeDo/History/Milestones/ucm128305.htm.
[11] FDA. FDA’s Risk Communication Research Agenda[EB/OL].(2014-09-03)[2015-06-18]. http://www.fda.gov/scienceresearch/specialtopics/riskcommunication/ucm227141.htm
[12] FDA. Guidance Drug Safety Information- FDA’s Communication to the Public[EB/OL]. (2007-03)[2015-06-16]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072281.pdf.
[13] FDA. Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs MarketedWith Approved Applications[EB/OL].(2012-06) [2015-06-16].http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm308206.pdf.
[14] 徐徕, 余伯阳, 杨依晗. 美国FDA 药品安全信息公开及启示[J].中国新药杂志, 2010,19(20):1841-1846.
[15] 樊迪. FDA 网站药品安全信息发布对我国启示[J]. 中国医院药学杂志,2014,34(13):1134-1138.
[16] FDA.CDER Offices and Divisions [EB/OL].(2015-06-26)[2015-06-16]. http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm075128.htm.